Baxter International Inc

BAX: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$64.00ZswcmrnWfjkhykk

Baxter Earnings: Strong Underlying Trends Boost 2024 Outlook Further

Narrow-moat Baxter turned in strong second-quarter results, and management raised its 2024 outlook on those trends. However, slightly higher near-term expectations do not materially change our $67 fair value estimate. Shares remain steeply undervalued, in our opinion, especially in a rising medical utilization and cooling inflationary environment that looks likely to continue boosting Baxter's profitability in the intermediate term.

Sponsor Center